Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STN1014101 ophthalmic solution in healthy volunteers and allergic conjunctivitis patients
jRCT2031250810Phase 1Recruiting
- Sponsor
- Santen Pharmaceutical
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of STN1014101 in allergic conjunctivitis (AC) (6 arms), sponsored by Santen Pharmaceutical. Primary endpoints: Safety, Subjective Ocular Symptom Score and 1 more. Started Jun 2026; status: recruiting.
02
Drugs
STN1014101
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on jRCT2031250810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250810.